Mebendazole is named as an intervention in 2 current clinical trials in our Egypt register. 2 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Sherief Abd-Elsalam (1). The most-studied condition is Colorectal Cancer.
Mebendazole was first approved in the US on 28 Jun 1974.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Mebendazole as Adjuvant Treatment for Colon Cancer
NCT03925662 · ClinicalTrials.gov ↗ · Colorectal Cancer
|
Phase 3 | Recruiting | Sherief Abd-Elsalam | Egypt |
|
Possible Efficacy and Safety of Mebendazole in Patients With Ulcerative Colitis Treated With Mesalamine
NCT06335160 · ClinicalTrials.gov ↗ · Ulcerative Colitis
|
Not applicable | Recruiting | Tanta University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
2 single-substance products containing Mebendazole on the HPRA medicines list.
No entry for Mebendazole in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Sherief Abd-Elsalam | 1 |
| Tanta University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Egypt | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Egypt register name Mebendazole as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Sherief Abd-Elsalam (1) and Tanta University (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 2 single-substance products containing Mebendazole, for example Vermox 100 mg tablets (JNTL Consumer Health I (Ireland) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Mebendazole has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mebendazole works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mebendazole works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mebendazole (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.